Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials
SHANGHAI, June 19, 2018 /PRNewswire/ — June 19, 2018, Luye Pharma Group announced that clinical applications of the company’s new compound candidate, extended release tablets (”LY03012”), a China Class 1.1…